# A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older

> **NCT07121192** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 776 (actual)

## Conditions studied

- Influenza, Human

## Interventions

- **BIOLOGICAL:** Flu mRNA (Formulation A)
- **BIOLOGICAL:** Flu mRNA (Formulation B)
- **COMBINATION_PRODUCT:** Comparator 1
- **COMBINATION_PRODUCT:** Comparator 2
- **COMBINATION_PRODUCT:** Comparator 3

## Key facts

- **NCT ID:** NCT07121192
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-08-25
- **Primary completion:** 2026-05-15
- **Final completion:** 2026-05-15
- **Target enrollment:** 776 (ACTUAL)
- **Last updated:** 2025-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07121192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07121192, "A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07121192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*